A phase III clinical trial (ARCHER 1050) in 2013–2015 compared the effectiveness of dacomitinib to the first generation gefitinib [74], and found dacomitinib significantly improved the progression-free survival over gefitinib in the first-line treatment of EGFR mutant NSCLC [74]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.